| Cancer |
|
" Do not follow where the path may lead. Go instead where there is no path and leave a trail." Ralph Waldo Emerson | |
![]() |
|


















| Cancer | RESEARCH RELATIONSHIPS CUNY click here Scientific Advisory Board click here Yale University click here From 1988 through 1998 the company funded research at the City University of New York, generating over 30 patents in the areas of tissue spectroscopy and optical imaging with applications in cancer detection. During that period the company also partnered with and/or conducted research at leading medical institutions including the National Cancer Institute (NCI), Memorial-Sloan Kettering Cancer Center, New York Hospital Cornell Medical Center, Yale University Department of OBGYN, etc. The Company has validated its technology in both pre-clinical and clinical testing, and is now focused on commercialization. Research and Product DevelopmentThe potential utility of native tissue fluorescence spectroscopy for in vivo cancer detection in humans was first discovered by Professor Robert R. Alfano, Distinguished Professor of Physics and Engineering at the City College of the City University of New York ("CUNY") in the early 1980's. Subsequent to the acquisition by the Company of LDI from Dr. Alfano in 1988, the company developed a research agreement with the Research Foundation of CUNY to provide research and development services. In June 1992, the Company and the Research Foundation of CUNY established the MPL (Mediphotonics Laboratory) at the Institute of Ultra fast Spectroscopy and Lasers ("IUSL") at the City of College of New York. Dr. Robert Alfano, Distinguished Professor of Physics and Engineering at City College and the Director of the IUSL, is also responsible for supervising the operations of the MPL. The IUSL includes approximately 60 scientists of which about 20 hold Ph.D's, 9 hold various other graduate degrees and about 30 are graduate students from which the MPL draws its research, talent and expertise. The staff of MPL, which is supervised by Dr. Alfano, developed our current prototype CD devices. MPL has also conducted in vitro pre-clinical testing of various human tissue types such as breast, cervical, colon and the upper aerodigestive tract, to develop the preferred optical scanning and emission wavelengths that yield the most definitive information about the native fluorescent characteristics of specific scanned tissue. The insight gained from this work has been the principal source of knowledge for the subsequently issued and pending patents which the Company either owns outright or possesses a world wide exclusive license, and which the Company regards as pioneering, blocking.and dominant in the area of cancer diagnosis using fluorescence (e.g. Patents 516--398). The information derived from this work was also the source for a number of scientific papers published in peer-reviewed journals and for presentations made at scientific symposia. This in vitro pre clinical research and development work also provided the starting basis for the optical scanning parameters for the Company's in vivo human clinical studies. The objective of the MPL is to research the use of light and ultra fast laser technology for cancer diagnosis and therapeutic purposes. The major projects of the MPL have been the development of the Company's prototype products, CD Scan, CD Ratiometer and CD Map, including the enhancement of fiberoptic attachments to enable devices to be used with various types of endoscopes and core biopsy needles. The MPL has additionally conducted in vitro preclinical evaluation of various tissues to determine the most appropriate excitation and emission wavelengths for use with a device for different types of human tissue and cancers, assembled the prototype CD products for use in vivo for human clinical trials and created the algorithms and computer software necessary for the accurate performance of the instruments.The Company established a Scientific Advisory Board in January, 1993 under the chairmanship of Professor Robert R. Alfano to provide critical review and analysis of its research and product development programs in the area of photonics (lasers and optics) and to serve as a source of information on new product ideas, new technologies and current research activities. Its function served the company well during the formal stages of its research. The board consists of Dr. Alfano and one other continuing member, Dr. Stimson Schantz. The Scientific Advisory Board will, in the future, be expanded to increase representation from the medical arts, including pathology, and will be staffed with medical specialists who are skilled in the medical fields of primary interest to the Company. They will also be called upon to advise us about priorities and unmet needs in their respective disciplines and in matters such as physician's habits and preferences that would bear on product design and configuration. Dr. Robert R. Alfano, Chairman click here Distinguished Professor of Science and Engineering, CCNY Dr. Alfano received his Ph.D. degree in Physics from New York University in 1972. He was a Research Staff Scientist at GTE Research Laboratory from 1964 to 1972. In 1972 he joined the Physics Department at The City College of CUNY as an Assistant Professor. Currently a Distinguished Professor of Science and Engineering, he serves as Director of the Institute for Ultrafast Spectroscopy and Lasers. He also serves as Director for the New York State Center of Advanced Technology for Ultrafast Photonic Materials and Applications; the NASA Institutional Research Program, and the DOE Center of Excellence for Laser Imaging in Medicine. Over the last twenty five years, he has published over 600 technical papers and has received 63 patents in the areas of laser spectroscopy, nonlinear optics, semiconductors, photosynthesis, medi-photonics, and optical imaging. For the past ten years, he has generated about $1M/yr. in research grants from NSF, NIH, AFOSR, ONR, NASA, ARO, Mediscience Technology, and other sources. He is a fellow of both the American Physical Society, and the Optical Society of America. Dr. Schantz received a B.A. from Harvard College in 1970 and Doctor of Medicine from the College of Medicine at the University of Cincinnati. His postdoctoral training was at Georgetown University Hospital, University of Illinois Eye and Ear Infirmary, and the University of Texas M.D. Anderson Cancer Center. He has held academic appointments at several medical teaching facilities including: The M.D. Anderson Hospital and Tumor Institute, the Department of Head and Neck Surgery at the University of Texas M.D. Anderson Cancer Center, Department of Surgery at Memorial Sloan- Kettering Cancer Center, Adjunct Scientist at the American Health Foundation, Senior Scientist at the Strang Cancer Prevention Society and currently Professor of Otolaryngology at the New York Eye and Ear Infirmary. Dr. Schantz is a member of numerous professional medical editorial boards including: Archives of Otolaryngology, Archives of Surgery, Cancer, Cancer Bulletin, Cancer Research, Head and Neck Surgery, New England Journal of Medicine, Otolaryngology, Year Book of Cancer, and Cancer Patient Follow-Up. Dr. Schantz has generated of a long list of research grants and has been the recipient of many professional honors and awards for his work in medical research. Dr. Schantz has published over the years some 145 peer-reviewed papers. He has published many invited articles in professional medical journals and has made a substantial contribution to many medical books mostly dealing in highly specialized areas of cancer studies and research. Dr. Schantz has participated in several research studies dealing with cancer detection through the use of the native cellular fluorescence technology pioneered by the Mediscience Technology Corporation. Some of the articles that he contributed to, with the collaboration of Professor Alfano and others, are entitled as follows: Raman spectoscopy as a molecular diagnostic tool for tissues, Fluorescence ratio mapping system for tissue diagnosis, Ultraviolet fluorescence system for mapping of head and neck tumors, Tissue autofluorescence spectroscopy as an intermediate endpoint for chemopreventive ag, Detecting retinoic acid induced biochemical alterations in squamous cell carcenoma using intrinsic fluorescence spectroscopy, Tissue autofluorescence as an intermediate endpoint in NMBA-induced esophageal carcinogenesis, Optical biopsy fiber based fluorescence based instrumentation, Influence of keratin on native cellular fluorescence of human skin, Native cellular fluorescence identities terminal squamous differentiation of normal epithelial cells in culture: a potential chemopreventive biomarker, Native cellular fluorescence and its application for cancer prevention, Second-harmonic tomography of tissues, Innate cellular fluorescence reflects alterations in cellular proliferation, Temporal polarization preservation in human breast tissue � a method for optical imaging, Second harmonic and two photon fluorescence histology of tissues, etc. FDA Approves Phase II in Vivo use of Medisience CD-Scan Optical System as Non-Significant Risk Device in Yale University/Mediscience significant Womens Health Study. (March 8, 1999) CHERRY HILL, NJ, March 8, 1999 - Peter Katevatis announced that Mediscience Technology Corp. (OTC.MDSC), developer and designer of non-invasive photonic technology used in medical diagnostic instruments that detect cancer/molecular changes based upon differentiations in the amount of light re-emitted from malignant and benign tissue, has entered into a research agreement with Yale University under which Frederick Naftolin Chairman OBGYN Yale University Dept. of Obstetrics and gynecology as the principle Investigator, will investigate the biological basis of fluorescence as applied to medically significant OBGYN Health issues using the Mediscience CD-Scan with FDA approval (Jan. 25, 1999) as a non-significant risk device for the proposed in Vivo Phase II Clinical investigation. In particular, the autofluorescence from specific areas will be examined to establish non-invasive diagnostic information of value in specificity and analysis to the OBGYN practitioner. The FDA approved clinical trial will obtain in Vivo and statistics which will lead o a broader multi-site effort. Mediscience has been conducting research in this field since 1988 and in a separate effort successfully completed a FDA approved phase I clinical evaluation with CD-Scan in human Patients under an NCI supported study of Aerodigesrtive (tobacco related) Cancer at Memorial Sloan-Kettering Hospital, New York City and is presently positioned to enter FDA Approved Phase II and Phase II (multi-sites) towards pre-market approval under the continued direction of principle investigator Stimson Schantz, MD. The potential annual market for clerical cancer and related woman health issues is approximately $1.25 Billion. Preliminary results of the Yale/Mediscience FDA approved in Vivo clinical trial are expected during 1999. Mediscience, a leader in this field, owns exclusive rights to 17 pioneering and early seminal patents in the field of Optical Biopsy and Optical Mammogrophy. Its CD-Scan and other prototype devices are based on its patented optical fluorescence spectroscopy technology. Certain matters discussed in this announcement contain forward-looking statements within the meaning of section 27A of the Securities act of 1933 and Section 21E of the Securities Act of 1934 that involve material; risks to, and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statement made herein. |